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The American Gastroenterological Association’s (AGA) Center for GI Innovation and 
Technology (CGIT) convened a consensus conference in December 2018, entitled, “Colorectal 
Cancer Screening and Surveillance: Role of Emerging Technology and Innovation to Improve 
Outcomes.”1 The goal of the conference, which attracted more than 60 experts in screening and 
related disciplines, including the authors of this paper, was to envision a future in which 
colorectal cancer (CRC) screening and surveillance are optimized, and to identify barriers to 
achieving that future. This white paper originates from that meeting and delineates priorities 
and steps needed to improve CRC outcomes, with the goal of minimizing CRC morbidity and 
mortality. 
 
The CGIT invited a diverse pool of prominent North American clinical and basic gastrointestinal 
researchers to attend the two-day consensus conference. A recently published meeting summary1 
detailed the organizational structure and targeted goals of the conference, from which this 
document emerges. The overarching objectives of the conference were to: (1) identify barriers to 
screening uptake, (2) assess the efficacy of available screening diagnostic methods, and (3) 
consider the potential integration of novel diagnostic approaches into screening and surveillance 
paradigms. These objectives were determined from responses to a pre-conference survey, which 
asked respondents to identify the current main limitations to screening, and to specify what kind of 
clinical research output they would most value. The most commonly mentioned limitation to 
screening was compliance with screening across the eligible population, and the most frequently 
mentioned desired output was development of an affordable, highly accurate, noninvasive test.   
 
Each of the authors of this white paper participated in the consensus conference and was chosen to 
develop this document based on their specific expertise in the above areas. Although the 
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conference featured a discussion of emerging endoscopic technologies, this topic will be featured 
in a follow-up document. This paper pertains specifically to North American practice, in which 
opportunistic colonoscopy is currently the dominant screening methodology.  
 
Summary Statement: A “one-size-fits-all” approach to CRC screening has not and is unlikely to 
result in increased screening uptake or desired outcomes due to barriers stemming from 
behavioral, cultural, and socioeconomic causes, especially when combined with inefficiencies in 
deployment of screening technologies. Overcoming these barriers will require (1) efficient 
utilization of multiple screening modalities to achieve increased uptake; (2) continued 
development of noninvasive screening tests, with iterative reassessments of how best to integrate 
new technologies; and (3) improved personal risk assessment to better risk-stratify patients for 
appropriate screening testing paradigms. Development of structured organized screening 
programs, rather than solely opportunistic screening driven by provider recommendation, will 
ultimately be needed to achieve target screening rates and reductions in CRC morbidity and 
mortality. Table 1 delineates key position statements and strategies for achieving those goals. 
 
 
Section 1. Strategic modifications to CRC screening can improve uptake and outcomes. 
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Position statement 1. A paradigm that addresses present barriers, incorporates shared decision-
making, and makes multiple modalities available will lead to improved screening uptake and 
the key desired outcomes of reduced incidence and mortality.  Including personalized risk as 
part of shared decision-making may improve uptake of screening and choice of test: 
colonoscopy for those at high risk, or initial noninvasive testing for those at lower risk. 
 
 
1.1.1. Current efforts to improve screening uptake have had modest but suboptimal 
success. 
In 2014 the National Colorectal Cancer Roundtable announced its “80% by 2018” program goal of 
achieving 80% screening uptake for adults aged 50 and older by 2018.2 The ambitious initiative set 
a high bar and achieved mixed results. “80% by 2018” showed that organizations could align over 
a common effort to improve screening uptake. Over 1,700 organizations across 50 states signed 
onto the initiative.3 Coordinated efforts modestly improved screening of all eligible Americans 
from 66.2% in 2014 to 67.3% in 2016.4,5 However, while some states approach rates close to 80%, 
most have fallen short. At least one-quarter of eligible Americans have not undergone any CRC 
screening and rates vary widely between states.6,7  
 
Opportunistic colonoscopy is the most prevalent strategy in the U.S. It is questionable if 80% 
uptake is achievable in a primarily opportunistic screening environment. Organized screening 
offers an opportunity for systematic improvements via several key elements: (1) defined target 
populations; (2) organized invitations to screen; (3) timely access and follow-up; (4) quality 
assurances; (5) tracking of outcomes, including complications; (6) greater protection against harms 
from over-screening8; (7) improved detection of advanced neoplasia (AN) when available tests 
(e.g., fecal immunochemical testing [FIT]) are used in a programmatic sequential process rather 
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than as a one-time test9,10; and (8) systematic opportunities for shared decision- making. In a 
shared decision-making process, which accounts for individual patients' needs and preferences11, 
patients are active partners, and clinicians offer acceptable medical options as well as the risk-
benefit profile for each option. 
 
 
An organized screening program could improve efficiency by incorporating noninvasive testing. A 
2018 Kaiser Permanente study reported that implementation of organized screening with both 
annual mailed FIT and colonoscopy alternatives led to attainment of ≥80% screening and decreased 
incidence of both early and advanced-stage CRC.12 Another study estimated that achieving ≥80% 
uptake by colonoscopy alone would require 16 million colonoscopies in the first year and 12 to 13 
million each year afterward; in contrast, a program offering both colonoscopy and FIT would 




1.1.2. Racial, socioeconomic, and geographic healthcare disparities limit screening 
efficacy. 
 
Access to screening is a major problem that disproportionately burdens African-American and 
Hispanic-American communities14-18, as well as individuals in rural areas.19-21 African- 
Americans experience higher rates of CRC than any other ethnic group in the U.S.22 
Differences in screening accounted for 42% of the disparity in CRC incidence between blacks 
and whites and 19% of the disparity in CRC mortality.7,23 National Health Information Survey 
(NHIS) data from 2000 through 2015 demonstrate that recent CRC screening was least likely 
to be reported by individuals with annual income <139% of the federal poverty level and those 
with less than a high school education, as well as subsets of some minorities.24 Berkowitz and 
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colleagues used county-level U.S. data to demonstrate substantial interstate and intra-state 
variation in CRC screening utilization, with pronounced differences in various racial cohorts.7 
 
 
1.1.3. Screening efficacy varies at multiple levels of service: patient, provider, and health 
care system. (See Supplemental material online at www.cghjournal.org) 
 
1.1.4. Integration of a stool testing option can increase participation rates in comparison to 
colonoscopy alone. 
In meta-analyses, the pooled sensitivity of programmatic FIT testing for CRC was 79% (95% 
confidence interval [CI], 69% to 86%) with a specificity of 94% (95% CI,  92% to 95%) and a 
mortality benefit of 20%-30%.25 FIT had been shown in diverse environments to outperform 
colonoscopy in terms of uptake.  In a Spanish controlled trial of over 55,000 patients randomized 
to either FIT or colonoscopy, the participation rate in the first cycle was greater for FIT than for 
colonoscopy (34.2% vs. 24.6%).26 Though there was limited uptake in this study, it illustrates that 
participation for FIT is higher than upfront colonoscopy in the first round, partially offsetting its 
lower single-application sensitivity for CRC. FIT is far simpler to administer than colonoscopy, 
which requires dietary manipulation, bowel preparation, and entails time off from work as well as 
the need for a chaperone and/or driver. 
 
In a cluster randomized design study, completion of screening in those offered fecal occult blood 
testing (FOBT) or colonoscopy (69%) was superior to those who were only recommended 
colonoscopy (38%). Nonwhite participants were more adherent to stool testing. This study shows 
that offering upfront stool testing as an option in addition to colonoscopy increases screening 
uptake.27 A challenge for health care systems that offer noninvasive testing is the need to follow-up 
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on positive results with referral for diagnostic colonoscopy and on negative results with repeat 
testing at the appropriate interval. 
 
A multi-target stool DNA test (MT-sDNA) has emerged as an alternative to FIT and has unique 
benefits and limitations in relation to FIT. MT-sDNA combines an immunoassay for 
hemoglobin with molecular assays for hypermethylated CpG islands (NDRG4 and BMP3) 
and mutant KRAS. In the pivotal trial comparing MT-sDNA to FIT, CRC detection was 
92% in the MT-sDNA arm and 74% in the FIT arm. Both stool tests detected a minority of 
AN, which was defined as cancer or advanced adenomas with any of the following 
characteristics: size ≥10 mm, high-grade dysplasia, or villous histology. MT-sDNA 
demonstrated a detection rate of 42%, compared to 24% for FIT. MT-sDNA outperformed 
FIT for detecting sessile serrated lesions (42% with MT-sDNA vs. 5% with FIT). The 
improved sensitivity of MT-sDNA over FIT comes at the price of reduced specificity (87% 
vs. 95%) for those without AN.28  
 
Other limitations of MT-sDNA include higher cost ($595, compared to approximately $25 for FIT 
testing)29 and lack of data on long-term outcomes of patients with negative and positive MT-
sDNA. Consequently, the optimal between-test interval is not yet defined.  There remains 
uncertainty in interpreting a positive MT-sDNA followed by negative colonoscopy for risk of an 
alternate aerodigestive cancer; although initial studies suggest no significantly increased risk of 
CRC in this scenario, further work is needed.30,31 
 
 
1.2.1. Strategy 1: Incorporate adjunct noninvasive testing to improve screening rates. 
In a Kaiser Permanente study, integration of an organized FIT program within an existing 
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organized colonoscopy program increased participation from 39% to 83%. The increase 
correlated with 25.5% and 52.4% reductions in CRC incidence and mortality, respectively.12 In 
comparison to MT-sDNA, FIT has a markedly reduced cost and a lower rate of false positives; in 
contrast, MT-sDNA has higher sensitivity.28 In a Markov model that assumed equal participation 
rates, FIT and colonoscopy were more effective and less costly than MT-sDNA.32 However, 
participation rate (i.e., uptake) is a critical variable that can determine a test’s effectiveness33; 
thus, individual preferences should be considered. Figure 1 depicts a shared decision-making 
model for screening test selection. 
 
 
1.2.2. Strategy 2: Minimize inappropriate colonoscopy usage. 
 
The common practice of performing re-screening and surveillance colonoscopy sooner than 
recommended by guidelines is ineffective, inefficient, and depletes limited resources that could 
have been allocated otherwise to address gaps in screening/surveillance (e.g., previously 
unscreened individuals facing barriers to colonoscopy).34 In the Study of Colonoscopy 
Utilization within the Prostate Lung Colorectal and Ovarian (PLCO) screening trial (N=3,876), 
up to a quarter of those without adenoma had undergone repeat colonoscopy by five years from 
their initial colonoscopy; by Year 7, 10.4% had undergone multiple colonoscopies.35 
Colonoscopy was underused in those with high-risk adenoma, which is the group at highest risk 
for subsequent CRC36, presumably those most likely to benefit from colonoscopy surveillance. 
Colonoscopy is inefficient when performed at earlier intervals in patients without adenoma, as 
the yield of finding AN is low.37,38 Following completion of a high-quality colonoscopy 
examination in which no colonic neoplasia is found, there is no need for further screening tests for 
a 10-year interval.39 We should actively foster a culture that minimizes inappropriate overuse of 




1.2.3. Strategy 3: Reconsider surveillance strategies for individuals with history of 
adenomatous polyps. 
Adenoma detection rates (ADRs), which are inversely correlated with post-colonoscopy CRC 
rates40,41, have increased over time42, though individual colonoscopists may find this metric 
challenging to increase.43-45 Increased ADRs result in expansion of the population placed into 
colonoscopy-based surveillance programs.42 In a setting where opportunistic screening 
predominates, the extent to which the burden of surveillance colonoscopy for polyps limits the 
ability to bring new patients to screening is undefined but may constrain colonoscopy 
resources.46,47 In addition, intensification of surveillance may not be necessary for everyone. 
 
Data suggest that history of small adenoma alone may not be a strong predictor of metachronous 
AN, and the benefit of surveillance colonoscopy at intervals less than 10 years is not entirely 
clear.48,49 Further, higher ADRs and consequently increased surveillance theoretically carry 
corresponding harms of additional procedures, including associated complications and cost50 — 
although a microsimulation model-based study contended otherwise. Meester and colleagues 
estimated that the lifetime risk for CRC was 12.5 per 1,000 patients for high adenoma detectors 
and 26.6 per 1,000 patients for low detectors. Although the estimated number of colonoscopies 
per 1,000 patients was greater in the “high adenoma detector group” by an average of 4.6%, there 
were fewer cancers and lower overall cancer-care costs, which offset the increased costs for 
screening.51 
 
One possible solution to the ever-increasing demand for surveillance colonoscopy is to prolong the 
surveillance interval for non-advanced adenomas. The recently updated U.S. Multi-Society Task 
Force (USMTF) on Colorectal Cancer surveillance guidelines have extended the interval between 
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colonoscopies for low-risk adenomas.52 Another approach is to consider noninvasive testing for the 
large subgroup of patients with low-risk adenomas as an alternative to surveillance colonoscopy. 
Interval FIT analyses can be used to detect missed or rapidly developing lesions in surveillance 
programs.53 In an English study, replacing three y arly colonoscopy surveillance procedures in 
intermediate-risk patients with annual FIT had the potential to reduce colonoscopies by 71% and 
significantly cut costs, but could miss 30%-40% of CRCs and 40%-70% of advanced adenomas.54 
T h e  o p t i m a l  w a y  t o  integrate noninvasive stool tests for cohorts with adenoma surveillance 
is not well defined and deserves further study. 
 
 
1.2.4. Strategy 4: Develop targeted methods to motivate and guide individuals 




Section 2. There is a need for continued development of noninvasive and minimally invasive 
tests for screening. 
 
Position Statement 2. The ideal noninvasive or minimally invasive screening test would be 




2.1.1. The ideal noninvasive or minimally invasive screening test has yet to be developed. 
 
An ideal test would identify lesions with high short-term potential to progress to CRC and should 
do so with high sensitivity and specificity in a convenient, low-risk, low-cost, and operator- 
independent manner. Such a test should be easy to complete and achieve high uptake in the 
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screening-eligible population. Presumably, a blood test would be the most effective vehicle, 
because of a markedly reduced barrier to compliance. 
 
 
CT colonography (CTC) and colon capsule endoscopy (CCE) are comparable to optical 
colonoscopy in their ability to detect lesions 10 mm or larger.55 However, these approaches have 
yet to achieve widespread adoption and are unlikely to do so.56 Limitations of these 
methodologies include the need for bowel preparation, and in the case of CCE, a prep currently 
more burdensome than colonoscopy, with a high proportion of screen failures.57 CTC and CCE 
show suboptimal detection of serrated lesions, which are flat and minimally vascular.58 
 
 
Efforts to develop and evaluate CRC screening markers need to address the following questions: 
 
(1) How can we optimally combine different types of markers to achieve high detection rates? (2) 
What is the desired combination of sensitivity and specificity? (3) Is AN the most appropriate 
target lesion metric, or is it preferable to have a marker that is also inclusive of advanced sessile 
serrated lesions? (4) How should we determine screening frequencies and intervals for tests using 
noninvasive biomarkers? (5) Will these biomarkers be generalizable to different molecular sub-
types of advanced lesions and CRCs? 
 
 
Noninvasive testing results should be reproducible, have low coefficient of variation at specified 
cut-offs, and be easy to sample in clinically realistic volumes. Their assessment via automated, 
high-throughput technology would facilitate quality control. 
 
 
2.1.2 The process by which novel diagnostics for CRC screening are developed should have 
a defined pathway with key milestones leading to eventual clinical use. 
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Comparing new CRC screening tests using CRC mortality as the endpoint will not be feasible 
given sample size requirements, time, and cost. Thus, simpler studies with surrogate endpoints 
(e.g., detection of AN) are needed. The comparator is a test with known abilities to improve 
CRC outcomes, such as FIT. 
 
 
A general pathway for cancer screening test development starts with a discovery phase to identify 
promising markers, followed by a validation phase to evaluate the performance of one or more 
markers in the intended clinical setting. This is followed by a clinical impact phase to assess 
whether use of the biomarker actually improves patient outcomes.59 Once an accuracy threshold 
is established, subsequent testing would entail randomization on an intention-to-screen basis.13 A 
2016 World Endoscopy Organization working group proposed a study design pathway for 
eventual integration of CRC-specific diagnostic tests into screening programs. Phase 1 would 
compare test accuracy in a retrospective cohort in CRC cases and controls. Phase 2 would entail a 
prospective evaluation of performance across the continuum of neoplastic lesions (advanced 
adenoma, CRC). Phase 3 would be an actual programmatic outcomes assessment, ideally with 
randomization versus an alternative screening modality (such as FIT); this phase would address 
patient uptake and participation; outcomes at one screening round would be addressed on an 
intention-to-screen basis. Phase 4, the final phase for consideration, would consist of a more 
comprehensive evaluation, including multiple rounds of screening, with additional assessments of 
safety and cost-effectiveness.60 
 
 
There are several genomic, proteomic, biochemical, epigenomic, and microbiome markers that 
might be integrated into screening tests, provided they address accuracy, ease of use, 
noni nvasiveness, and cost-effectiveness. Biomarkers can be categorized into studies that consider 
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CRC detection alone and those that combine CRC detection with prevention (i.e., via detection of 
precancerous lesions). For those that seek a preventive effect, detection of advanced adenoma 
(lesion ≥10mm in size or of any size with advanced features) is an important endpoint. The 
rationale for considering advanced adenoma comes from studies in which the cumulative CRC 
incidence by initial adenoma status is significantly higher in those with an advanced adenoma, but 
not in those with any non-advanced adenoma.36 
 
The most appropriate target lesion for noninvasive screening is currently not entirely defined.  The 
USMTF describes AN as inclusive of CRC and adenomas   with high-grade dysplasia or with 
≥25% villous histologic features or measuring ≥1 cm, but their definition of AN does not include 
sessile serrated lesions even of advanced size.52 In some instances, such as in the pivotal trial for 
MT-sDNA, investigators assessed an endpoint that is also inclusive of advanced sessile serrated 
lesions.28  Further work will need to link the added benefit and cost of these differing screening 
target endpoints to endpoints pertaining to cost, cancer incidence, and mortality. 
 
2.2.1. Strategy 5: Set an aspirational target for developing a minimally invasive, easy-to-use 
test that will detect advanced adenomas and advanced serrated lesions with a one-time 
sensitivity and specificity of no less than 90%. 
At present, new diagnostic tests need to be evaluated against a comparator. It is reasonable to 
compare new biomarkers to FIT with respect to sensitivity, specificity, and mortality, as well as 
to accuracy, uptake, and ease of use. We propose an aspirational goal of developing a non- 
invasive test capable of detecting advanced adenomas and advanced serrated lesions, as described 
in the USMTF guidelines52, at a rate comparable to colonoscopy (≥90%) with a sensitivity of 
90%. Such a marker would, in terms of detection capabilities, challenge the current rationale for 
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upfront colonoscopy, as it would have comparable sensitivity with colonoscopy along with high 
specificity for identifying individuals with important target lesions. When considering aspirational 
rates of specificity for AN for noninvasive markers, it is worth noting that no neoplasia is found 
in a high percentage of average-risk patients undergoing screening colonoscopy. In this sense, no 
direct therapeutic benefit of colonoscopy for cancer prevention in those cases is derived.61 Wh n 
considering the rates of colonoscopy for screening for advanced precancerous lesions the rate of 
"negative colonoscopy findings" is even higher.    
 
Future integration of CTC and CCE uptake into screening will require improvements from 
existing technology, including (1) development of methodologies to eliminate or reduce bowel 
preparation; (2) identification of methodologies to improve imaging of suboptimally detected 
lesions such as sessile serrated polyps and certain segments of the colorectum; (3) integration of 
imaging technologies with artificial intelligence to detect and differentiate lesions and reduce 
provider reading times; (4) enhanced accuracy; and (5) development of methodologies with 
improved ease of use, potentially allowing for home use. 
 
 
Section 3. Improved personal risk assessment is critical to optimized programmatic 
screening. 
Position statement 3. There is a need for improved assessment of individual risk to enhance the 
process of risk stratification for risk-based screening and surveillance. 
 
 
3.1.1. Current approaches to risk stratification frequently utilize inaccurate and incomplete 
information, limiting appropriate decision-making for screening and surveillance. 
Current guidelines for risk assessment utilize familial and personal colorectal neoplasia risk. 
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However, there are numerous additional factors (e.g., sex, race, smoking, body mass index 
[BMI]) associated with CRC risk that could potentially be used to tailor screening.62 Risk 
stratification requires reliable information of the considered risk factors. Family history and prior 
adenomatous polyp burden are frequently challenging to obtain reliably and often not well 
recorded. Less than 40% of individuals with a family history of CRC have discussed this 
information with their health care provider.63 Family history is often not obtained due to a lack of 
patient awareness and the provider’s limited ability to derive and record the information.63-65  
 
Currently the burden of ensuring accuracy of family history is typically placed on providers at the 
time of clinical visits. One disadvantage of this model is that family histories may remain static 
following initial documentation, even if the patient subsequently learns of new, pertinent family 
history. The increasing use of patient portals presents an opportunity to both involve patients in 
their own care as well as to keep family histories updated and/or accurate. Evaluation of this model 
for patient data entry outside of clinical visits deserves further study.   
 
 
3.1.2. Strategy 6: Enable electronic health record (EHR) integration to permit providers 
working in different settings to accurately estimate a mutual patient’s risk based on all 
pertinent data. Currently, barriers exist to interrogating a patient’s EHR outside of the patient’s 
health system in order to reliably obtain the requisite personal or familial history for risk 
stratification. (See Supplemental material online)  
 
 
3.2.1. There are multiple significant challenges to incorporating new approaches to risk 
assessment in CRC screening and surveillance. 
Risk assessment tools have typically utilized different endpoints. “CRC risk” can either be 
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considered as a future/lifetime risk for CRC or as the current or present risk for CRC or AN. The 
National Cancer Institute’s Risk Assessment Tool for Colorectal Cancer has been prospectively 
validated for the outcome of AN at colonoscopy.66,67 Other models have been used for estimating 
long-term or lifetime risk for CRC.68,69 
 
 
Incorporating risk assessment tools into clinical practice will be challenging. Systems would 
integrate with EHRs, identifying factors already available in the EHR and querying the user for 
information not present in the EHR, with the end result of producing risk estimation with or 
without linkage to a preferred screening strategy. Models require testing and validation in the 
target population, along with determining whether and by how much they improve CRC 
screening uptake, adherence, satisfaction, and efficiency. It will be important to ensure that 
overall participation rates are not affected adversely due to the complexity and additional 
administrative burden from using risk stratification. 
 
 
3.2.2. Risk assessment tools must better define individual risk to stratify patients for 
appropriate CRC screening test selection. 
Individuals with a higher likelihood of advanced adenoma or CRC would be directed to 
colonoscopy, currently the most sensitive test with the ability to remove advanced adenoma and 
some early-stage CRCs. Lower-risk individuals would be directed to less-invasive approaches 
that offer a reduced side effect profile but may have higher uptake. Numerous predictive models 
have been developed to predict CRC risk and guide screening decision-making.70-72 I  a 
predictive model using age, sex, waist circumference, cigarette smoking, and family 
history of CRC, AN detection was 10 times higher in the high-risk group than in the very low- 
risk group.72 In a comparison of 17 previously published risk models, Peng and colleagues found 
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only a modest ability to predict the presence of AN; the authors recommended that subsequent 
models consider integrating genomic features, with the goal of increasing discriminatory power.73 
 
 
3.2.3. Strategy 7: Integrate CRC risk assessment approaches incorporating 




3.2.4. There is a need for improved assessment of individual risk to improve risk 
stratification for re-screening and surveillance. 
Much less work has been done in the area of risk stratification for re-screening and general 
surveillance as compared with primary screening. Currently, re-screening tests other than 
colonoscopy are infrequently offered to a patient with a previous negative colonoscopy. A 
microsimulation analysis by Knudsen and colleagues found that in persons with a negative 
screening colonoscopy, re-screening using any of the other recommended strategies provided the 
same subsequent benefit in terms of life-years saved and with fewer complications and lower 
costs than colonoscopy every 10 years.74 Optimal predictive models to risk-stratify the patient 
after colonoscopy will need to incorporate findings of that colonoscopy (i.e., presence and extent 
of neoplasia) with other associated predictors for CRC to guide future clinical decision-making. 
 
Some associated risk factors for metachronous AN, including age, sex, and location in the 
proximal colon, are currently not used in determining the surveillance interval.75 Not considering 
these and possibly other factors may explain the relatively poor discriminatory power for 
estimating risk for AN and the low yield of surveillance colonoscopy, especially for persons with 
non-advanced neoplasia. In a pooled analysis of data from 9,167 adults aged 22-80 with previously 
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resected colorectal adenomas, risk factors such as older age, number and size of adenomas, and 
villous histology – each of which guides delineation of surveillance intervals – all separately 
increased the risk of future metachronous AN by ORs of no more than 1.7.76 Several studies have 
examined risk for AN on the second surveillance colonoscopy based on the previous two 
colonoscopies.77-80 We envision a future in which guided risk assessment accounts for the patient’s 
past colonoscopy historical profile. Electronic health record (EHR) capture of data needs to be 
more accurate and reliable to ensure accurate population-based data in relation to CRC screening. 
Interfacing between EHRs across institutions is a further challenge.81,82 As health care systems and 
EHRs continue to evolve, subsequent studies will be able to link baseline findings, phenotypic 
features, and surveillance colonoscopy to hard clinical endpoints of CRC incidence and mortality. 
 
3.3.1. The consequences of expanding screening recommendations to an earlier age have 
yet to be defined. 
While the overall incidence of CRC has declined over the last two decades in the U.S., it has 
risen in those under the age of 50.83 The proportion of CRC in adults under 50 has doubled since 
1990.84 The increase in the incidence of CRC in the 40-49-year-old group, which amounts to a 
roughly 1.3% annual risk increase since the mid-1990s84, has heightened interest in initiating 
screening earlier (age 45). Such an approach would prevent CRC in an estimated three per 1,000 
persons screened, or an estimated 66,000 cancers in 22 million eligible persons aged 45-49.85 
Potentially, knowledge of such benefits might motivate more people aged 50-54 to get screened, 
possibly enabling identification of earlier-stage cancers, though there are no clear data 
supporting this concept. Moreover, there are multiple challenges to initiating screening at age 
45.86 One potential consideration is that if patients are screened by colonoscopy, they would 





In areas of high colonoscopy demand, it is unclear how the need to screen younger patients would 
be balanced against limited endoscopic capacity, as initiating screening at age 45 would add 21 
million people to the current pool of 94 million eligible persons – an increase of 22%. Moreover, 
a cost-effectiveness analysis showed that greater benefit, at lower cost, could be achieved by 
increasing screening participation rates for currently unscreened older and higher- risk persons 
than by screening lower-risk, younger patients.85 Steering younger individuals toward low-cost 




3.3.2. Strategy 8: Support research to better characterize the benefits and risks of 
initiating CRC screening at a younger age. 
Studies should focus on the cost-effectiveness of screening younger patients, the performance 
characteristics of screening tests in specific cohorts of younger people, and how factors such as 
BMI, lifestyle, and family history impact risk in younger patients. There is also a need for studies 
to address adherence to different screening test methods by younger patients, as well as their 
likelihood of screening participation and compliance with recommended surveillance intervals. 
The increasing incidence of CRC in people under 50 years of age may be secondary to changes in 
dietary patterns, activity levels, the gut microbiome, or other factors. The impact of these factors 
on the risk of colorectal cancer could be measured with novel assays that assess the colon 






In the opportunistic screening environment in the U.S., where colonoscopy is the most prevalent 
method, CRC screening has not reached aspirational goals in terms of uptake, reduction in CRC 
incidence, and disease burden. Ultimately, the development of organized screening programs that 
can identify and navigate the unscreened to screening should be considered. Efforts to 
significantly decrease CRC incidence rates and disease-related outcomes will require greater 
integration of additional alternative testing modalities to colonoscopy to increase uptake. Stool 
testing by FIT is currently the most readily available alternative, though novel molecular 
biomarkers hold promise for making screening more accurate and efficient. 
 
 
The desired future of CRC screening is one in which screening is readily available to at-risk 
individuals, with no significant disparities in access to screening. Such a future will also feature 
noninvasive testing methods that are highly accurate, easy to use, and facilitate referrals to 
colonoscopy only for those patients most likely to benefit. 
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Table 1: Barriers and Strategies for Improving Colorectal Cancer Screening in the United States 
 
Position Statement 1. A paradigm that 
acknowledges present barriers, incorporates 
shared decision-making, and makes 
multiple modalities available will lead to 
improved screening uptake and outcomes. 
Position Statement 2. The ideal non-
invasive or minimally invasive screening 
test would be widely adopted and identify 
those at risk for CRC with high accuracy. 
Position Statement 3. There is a need 
for improved assessment of individual 
risk to better stratify patients for 
appropriate screening and surveillance. 
Barriers Barriers Barriers 
1.1.1. Suboptimal screening uptake  2.1.1. Lack of an ideal non-invasive or 
minimally invasive screening test 
3.1.1. Inaccurate and incomplete 
information to inform risk stratification  
1.1.2. Racial, socioeconomic, and 
geographic healthcare disparities  
3.2.1. Challenges to incorporating new 
approaches to risk assessment in CRC 
screening and surveillance 
1.1.3. Varying screening efficacy varies at 
multiple levels of service 
2.1.2. Lack of a defined pathway and key 
milestones for developing novel 
diagnostics for CRC screening 
3.2.2. Suboptimal definition of 
individual risk in risk assessment tools 
1.1.4. Challenges to integration of a stool 
testing option  
3.2.3. Need for improved assessment of 
individual risk to better stratify patients 
for appropriate re-screening and 
surveillance 
3.3.1. Undefined consequences of 
expanding screening recommendations 
to an earlier age  
Strategies Strategies Strategies 
1. Incorporate adjunct non-invasive testing 
to improve screening rates. 
5. Set an aspirational target for developing 
a minimally invasive, easy-to use test that 
will detect advanced adenomas and 
advanced serrated lesions with a one-time 
sensitivity and specificity of no less than 
90%. 
6. Enable EMR integration to permit 
providers working in different settings 
to accurately estimate a mutual patient’s 
risk based on all pertinent data. 
2. Minimize inappropriate colonoscopy 
usage. 
7. Integrate CRC risk assessment 
approaches incorporating 
lifestyle/anthropometric, environmental, 
and polygenic risk factors. 
3. Reconsider surveillance strategies for 
some individuals with low risk 
8. Support research to better 
characterize the benefits and risks of 
 
adenomatous polyps as candidates for 
surveillance by noninvasive methods. 
initiating CRC screening at a younger 
age. 
4. Develop targeted methods to motivate 










Figure 1. Risk Assessment Model with Shared Decision-Making l for CRC Screening.  
Colonoscopy is recommended for high-risk patients, such as individuals with a family history of 
colorectal cancer (CRC) in a first-degree relative. Better risk assessment tools are needed to risk-
stratify patients’ risk of CRC and guide the initial screening test of choice. Shared decision-
making is incorporated into risk assessment. Noninvasive testing is prioritized for those patients 
with lower risk profiles; colonoscopy is prioritized for those at higher risk for CRC. When 
noninvasive tests (i.e., stool tests) are negative, risk stratification of patients can guide 
establishment of the post-test interval for re-screening. The interval may be delayed for lower-
risk patients with negative stool test results. Those with no neoplasia or only non-advanced 
neoplasia at colonoscopy may be considered for future noninvasive testing. Tools for re-
stratification post-colonoscopy should incorporate procedural findings to define either future 
surveillance intervals for colonoscopy or suitability for alternative noninvasive testing.   
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1.1.3 Screening efficacy varies at multiple levels of service: patient, provider, and health 
system-wide. 
More than 20 million eligible U.S. adults have not participated in CRC screening. Failure to 
complete screening can stem from socioeconomic barriers, including challenges entering the 
health care system (e.g., lack of insurance coverage); inability to access a location that provides 
screening in a reasonable time frame; inability to find a trusted provider to guide the patient 
through the screening process1,2; and inability to take time off from work for colonoscopy and/or 
find transportation for the procedure. Other barriers include personal objections related to 
hygiene risk, fear of testing procedures, and embarrassment.3-5 
 
 
Primary care physicians (PCPs) can serve as important advocates for CRC screening. A 
systematic review showed that PCP recommendations improved screening rates for both 
colonoscopy and stool-based testing.6,7 However, unconscious biases can limit this effect: racial 
disparities in physician recommendations lead to disparities in screening.8 A program that 
provides oversight of screening access and completion in the U.S. may improve future screening 
uptake and the ability to scale screening efforts beyond individual private health systems. 
2  
 
1.2.4 Strategy 4: Develop targeted methods to motivate and guide individuals 
undergoing first-time screening. 
Motivation by peers, community leaders, and celebrities can potentially influence patient behavior. 
Currently, it is unclear how to select individuals who may benefit most from navigator- based, 
provider-based, or digital navigation methods. Several studies have successfully implemented 
patient navigation programs to improve CRC screening compliance.9-14 Additionally, the American 
Cancer Society has developed materials to facilitate shared decision–making for CRC screening.15 
However, there are few high-quality randomized studies that apply a rigorous comparative 
assessment of different methods to improve screening outcomes.16 Although digital tools are 
appealing, an estimated 19% of Americans – including 34% of those with less than a high school 
degree – do not own a smartphone.17,18 Thus, digital approaches alone are unlikely to reach a 





Navigation efforts targeting patients who would otherwise undergo screening anyway is a poor 
use of resources. A key targeted population for interventions should be those who fail to complete 
prior screening efforts. When less-invasive methods such as fecal immunochemical testing (FIT), 
multi-target stool DNA (MT-sDNA), colon capsule endoscopy (CCE), and computed 
tomographic colonography (CTC) are positive, follow-through to colonoscopy completion is the 
rate-limiting step for enhancing screening effectiveness. In a review of electronic medical records 
(EMRs) of 1,267 low socio-economic status patients aged 50-64 years with positive FIT results, 
42% failed to undergo follow-up colonoscopy within one year.19 In a Kaiser Permanente study of 
patients with a positive FIT, if colonoscopy was delayed >6 months, there was a higher risk of any 






3.1.2 Strategy 6: Enable EMR integration to permit providers working in different 
settings to accurately estimate a mutual patient’s risk based on all pertinent data.  
We envision a future where the EMR is integrated across health systems and information 
needed for risk assessment is readily available. Development of a systemic methodology to 
verify a patient’s individual and familial neoplasia burden will not only enable monitoring of 
compliance with guideline-recommended screening intervals; it will also allow for high-quality 
assessment of additional predictive variables in risk prognostication. This will need to be done 
without violating patient privacy. 
 
3.2.3 Strategy 7: Integrate CRC risk assessment approaches incorporating 
lifestyle/anthropometric, environmental, and polygenic risk factors. 
The modest ability of current models to predict risk of advanced neoplasia (AN) underscores 
the need for alternative approaches. In one colonoscopy cohort study a greater than 30-pack-
year history of smoking yielded an odds ratio (OR) of 3.39 (95% CI, 2.47-4.66) for the 
presence of advanced adenoma; this was significantly greater than the OR for having a first-
degree relative with CRC: 1.37 (95% CI, 0.94-2.00).21 Multiple anthropometric measures have 
been associated with CRC risk including BMI and hip-to-waist ratio.21,22 
 
 
Jeon and colleagues created a potential prototype of a model that incorporates genetic and 
environmental factors. The combined genetic risk score (based on 63 CRC-associated single- 
nucleotide polymorphisms [SNPs]) and environmental risk score (based on 19 lifestyle and 
environmental factors) had an area under the receiver operating characteristic (ROC) curve value 
4 
 
for estimating CRC risk of 0.63 (95% CI, 0.62–0.64) for men and 0.62 (95% CI, 0.61-0.63) for 
women. The study shows polygenic risk score in combination with environmental risk factors 
and family history offer promise for improved risk stratification. Similar approaches 
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